Cargando…

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer

BACKGROUND: Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer (PC) expression has theranostic utility. OBJECTIVE: To elucidate PC PSMA expression and associate this with defective DNA damage repair (DDR). DESIGN, SETTING, AND PARTICIPANTS: Membranous PSMA (mPSMA) expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paschalis, Alec, Sheehan, Beshara, Riisnaes, Ruth, Rodrigues, Daniel Nava, Gurel, Bora, Bertan, Claudia, Ferreira, Ana, Lambros, Maryou B.K., Seed, George, Yuan, Wei, Dolling, David, Welti, Jon C., Neeb, Antje, Sumanasuriya, Semini, Rescigno, Pasquale, Bianchini, Diletta, Tunariu, Nina, Carreira, Suzanne, Sharp, Adam, Oyen, Wim, de Bono, Johann S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853166/ https://www.ncbi.nlm.nih.gov/pubmed/31345636 http://dx.doi.org/10.1016/j.eururo.2019.06.030

Ejemplares similares

HER3 Is an Actionable Target in Advanced Prostate Cancer
por: Gil, Veronica, et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
por: Sheehan, Beshara, et al.
Publicado: (2022)

CD38 in Advanced Prostate Cancers
por: Guo, Christina, et al.
Publicado: (2021)

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
por: Zafeiriou, Zafeiris, et al.
Publicado: (2019)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
por: Rescigno, Pasquale, et al.
Publicado: (2018)

Genomics of lethal prostate cancer at diagnosis and castration resistance
por: Mateo, Joaquin, et al.
Publicado: (2020)

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
por: Sumanasuriya, Semini, et al.
Publicado: (2021)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
por: Carreira, Suzanne, et al.
Publicado: (2021)

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
por: Mehra, Niven, et al.
Publicado: (2018)

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
por: Nava Rodrigues, Daniel, et al.
Publicado: (2018)

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer
por: Grochot, Rafael, et al.
Publicado: (2023)

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
por: Welti, Jonathan, et al.
Publicado: (2016)

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
por: Kolinsky, M.P., et al.
Publicado: (2020)

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
por: Guo, Christina, et al.
Publicado: (2023)

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
por: Mateo, Joaquin, et al.
Publicado: (2020)

Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital
por: Bianchini, Diletta, et al.
Publicado: (2017)

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
por: Lorente, David, et al.
Publicado: (2016)

Application of Liquid Biopsies in Cancer Targeted Therapy
por: Sumanasuriya, S, et al.
Publicado: (2017)

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
por: Li, Xiangyi, et al.
Publicado: (2018)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products
por: Ferrarini, Alberto, et al.
Publicado: (2018)

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
por: Mateo, Joaquin, et al.
Publicado: (2018)

Acquiring evidence for precision prostate cancer care
por: Mateo, J., et al.
Publicado: (2017)

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
por: Minchom, Anna, et al.
Publicado: (2020)

Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
por: Sowalsky, Adam G., et al.
Publicado: (2022)

Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
por: Cato, Laura, et al.
Publicado: (2017)

Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features
por: Perez-Lopez, Raquel, et al.
Publicado: (2018)

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
por: Pezaro, C, et al.
Publicado: (2013)

The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer
por: Adamson, Beth, et al.
Publicado: (2023)

Targeting radioresistance and replication fork stability in prostate cancer
por: Li, Xiangyi, et al.
Publicado: (2022)

Determination of HER2 Amplification Status on Tumour DNA by Digital PCR
por: Garcia-Murillas, Isaac, et al.
Publicado: (2013)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients
por: Nanou, Afroditi, et al.
Publicado: (2018)

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice
por: Patel, Priyanka H., et al.
Publicado: (2022)

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
por: Lorente, David, et al.
Publicado: (2016)

Consensus Procedures in Oncological Imaging: The Case of Prostate Cancer
por: Fanti, Stefano, et al.
Publicado: (2019)

Acute kidney injury due to abdominal compartment syndrome caused by duodenal metastases of prostate cancer
por: Gurel, Ali
Publicado: (2015)

Genomic correlates of clinical outcome in advanced prostate cancer
por: Abida, Wassim, et al.
Publicado: (2019)

FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
por: Elbauomy Elsheikh, Somaia, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_5sl0oqu4hv37j8mej6a4138uu9